Lucid Diagnostics Inc (LUCD) Stock AnalysisLUCDStock AnalysisLucid Diagnostics Inc

Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Lucid Diagnostics Inc (LUCD) appears to be a good buy right now, given its recent price of $0.99, which is significantly lower than the analyst price target of $9.50. Additionally, the stock has shown a positive momentum with a 5-day change of +2.81% and a 20-day change of +13.74%. The main risk is its high net loss, with a net income of -14,715,000 USD reported in Q2 2026, which indicates ongoing financial challenges that could affect future performance.